Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD)

Completed · Phase 4

Conditions studied: PTSD

In brief

To study the potential therapeutic effects of topiramate (Topamax) in the treatment of PTSD.

Key facts

Study ID

NCT00203463

Run by

Tuscaloosa Research & Education Advancement Corporation

People needed

40

Starts

2001-07-01

Expected to finish

2004-09-01

Last updated by the study team

2009-07-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of PTSD DSM-IV criteria
• No substance abuse/dependence for the previous 2 months (except for nicotine and caffeine)
• Free of psychotropic medication, for 2 weeks (except 6 weeks for fluoxetine)
• Normal physical and laboratory examination (lab profile listed below)
• Negative urine screen for drugs of abuse
• Women of childbearing potential must be using nonpharmacologic medically approved methods of birth control
• Signed informed consent
• Male or female, any race or ethic origin

You may not qualify if…

• Lifetime history of bipolar, psychotic, or cognitive disorders
• Suicidal, homicidal, or psychotic
• Diagnosis of bulimia or anorexia nervosa
• History of sensitivity to topiramate
• General medical conditions or ongoing treatment that contraindicate the use of topiramate, such as seizure disorder or use of MAO inhibitors.
• Women planning to become pregnant or breastfeed during the study

Where it is running

• Tuscaloosa Research & Education Advancement Corporation — Tuscaloosa, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.